Exclusive Journals Coverage

Exclusive Journals Coverage articles provide quick insight and additional author perspectives on select studies recently published in Journal of Clinical Oncology and Journal of Oncology Practice.

Sep 23, 2014
I am originally from Manila, Philippines. My mother, a medical oncologist, inspired me to enter the field of oncology. She is my personal hero and idol, although she doesn't know this. She is hardworking, patient, and dedicated to her patients, and I feel the meaning of true vocation whenever I see her work. She is an instrument of healing. She's...
Sep 22, 2014
Among the four patients with DLBCL who had a complete response (CR), three are still alive, with ongoing survival-times ranging from nine to 22 months from treatment. 
Sep 15, 2014
Among the important findings was that for every one “realistic” statement doctors made, they made three hopeful statements indicating that the treatment could bring positive outcomes, such as lengthening the life of the child. 
Sep 02, 2014
A new study in the Journal of Clinical Oncology (JCO) found that patients who were admitted to hospice in the last three days of life were significantly more likely to have a hematologic malignancy, to be male, married, and younger than age 65.
Aug 25, 2014
The study found that five-year survivors of adolescent and adult Hodgkin lymphoma (HL) who received more than 36 gray (Gy) of radiation to the para-aortic lymph nodes and spleen had a significantly higher risk of developing diabetes mellitus . . .
Aug 11, 2014
The study showed that in 90% of patients with metastatic lung adenocarcinoma whose tumors contained common EGFR mutations (deletion in exon 19 or L858R), progression free survival (PFS) was 13.6 months for afatinib and 6.9 months for chemotherapy . . .
Aug 04, 2014
Statins, the widely used drugs taken to lower cholesterol, might have another benefit—increasing survival among patients diagnosed with colorectal cancer. That’s according to a Journal of Clinical Oncology (JCO) study, published online, ahead of print, August 4.
Jul 28, 2014
“This study shows that—as opposed to an FDA black-box warning of tumor progression, shortened survival, and thrombotic risks—reimbursement has far greater impact in terms of changing physician behavior,” said study first author, Dawn L. Hershman, MD, MS . . .
Jul 16, 2014
Perspective from L. Michael Glodé, MD, FACP, FASCO, an IDEA Mentor
Jul 14, 2014
To explain the rise in oropharyngeal squamous cell carcinoma (OPSCC), researchers turned to another historic trend—the increase, since the late 1970s, in the number of people carrying human papillomavirus (HPV), an infection known to cause OPSCC . . .

Pages